REVIEW

Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy [version 1; peer review: 3 approved]

Lama Ghazi, Paul Drawz

Division of Renal Disease and Hypertension, Department of Medicine, University of Minnesota, Minnesota, MN, USA

V1 First published: 21 Mar 2017, 6(F1000 Faculty Rev):297
<https://doi.org/10.12688/f1000research.9692.1>

Latest published: 21 Mar 2017, 6(F1000 Faculty Rev):297
<https://doi.org/10.12688/f1000research.9692.1>

Abstract

The renin-angiotensin-aldosterone system (RAAS) plays a fundamental role in the physiology of blood pressure control and the pathophysiology of hypertension (HTN) with effects on vascular tone, sodium retention, oxidative stress, fibrosis, sympathetic tone, and inflammation. Fortunately, RAAS blocking agents have been available to treat HTN since the 1970s and newer medications are being developed. In this review, we will (1) examine new anti-hypertensive medications affecting the RAAS, (2) evaluate recent studies that help provide a better understanding of which patients may be more likely to benefit from RAAS blockade, and (3) review three recent pivotal randomized trials that involve newer RAAS blocking agents and inform clinical practice.

Keywords

renin-angiotensin-aldosterone system , hypertension , blood pressure control , anti-hypertensive drugs , blocking agents

Open Peer Review

Approval Status

	1	2	3
version 1 21 Mar 2017			

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **AK Johnson**, University of Iowa, Iowa City, USA
2. **Anton van den Meiracker**, Erasmus Medical Centre, Rotterdam, The Netherlands
3. **Bertram Pitt**, University of Michigan School of Medicine, Ann Arbor, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Paul Drawz (pedrawz00@yahoo.com)

Competing interests: The authors declare that they have no competing interests.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2017 Ghazi L and Drawz P. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Ghazi L and Drawz P. **Advances in understanding the renin-angiotensin-aldosterone system (RAAS) in blood pressure control and recent pivotal trials of RAAS blockade in heart failure and diabetic nephropathy [version 1; peer review: 3 approved]** F1000Research 2017, 6(F1000 Faculty Rev):297 <https://doi.org/10.12688/f1000research.9692.1>

First published: 21 Mar 2017, 6(F1000 Faculty Rev):297 <https://doi.org/10.12688/f1000research.9692.1>

New and existing anti-hypertensive drugs affecting the renin-angiotensin-aldosterone system

There are well-established drugs that interfere with the renin-angiotensin-aldosterone system (RAAS) at several sites, including (1) angiotensin-converting enzyme inhibitors (ACEIs), (2) angiotensin II type I (AT_1) receptor blockers (ARBs), (3) direct renin inhibitors (DRIs), (4) mineralocorticoid receptor antagonists (MRAs), and even (5) beta blockers, the last of which may be considered partial inhibitors (Figure 1)¹⁻⁴. In this section, we briefly review trials demonstrating benefits of ACEIs/ARBs and then discuss recent advances and newer agents that block the RAAS at different sites.

Angiotensin-converting enzyme inhibitors and angiotensin II type I receptor blockers

ACEIs and ARBs have been the cornerstone of RAAS inhibition for years and are key therapeutic options in patients with hypertension (HTN), reducing cardiovascular morbidity and mortality and improving renal outcomes. In the HOPE (Heart Outcomes Prevention Evaluation)⁵, MICRO-HOPE (The Microalbuminuria, Cardiovascular, and Renal Outcomes in HOPE)⁶, EUROPA (European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease)⁷, SOLVD (Studies of

Left Ventricular Dysfunction)⁸, and Captopril Prevention Project⁹ studies, ACEIs were beneficial in reducing rates of death, myocardial infarction, stroke, coronary revascularization, cardiac arrest, and heart failure, complications related to diabetes and heart failure. Both the RENAAL¹⁰ and IDNT¹¹ trials demonstrated a renoprotective effect of RAAS inhibition in nephropathy due to diabetes. ACEIs and ARBs are considered to be equally beneficial on the basis of studies such as ONTARGET¹², which compared telmisartan and ramipril, and DETAIL¹³, which compared telmisartan with enalapril and found no difference in progression of diabetic nephropathy.

Azilsartan, a novel ARB, has been shown to have superior efficacy in reducing blood pressure (BP) when compared with olmesartan or valsartan¹⁴⁻¹⁶. Azilsartan 80 mg reduces BP more efficaciously than the optimal and highest tolerated dosage of both olmesartan (40 mg) and valsartan (320 mg) using 24-hour ambulatory BP monitoring and without increase in adverse effects¹⁴. A recent analysis of a German registry confirmed these results; among 3,849 patients with essential HTN, 61% of patients who initiated therapy with azilsartan achieved a BP target of less than 140/90 mmHg compared with 56% of those who were started on an ACEI¹⁷. Azilsartan may be more effective at lowering BP because of its more potent

Figure 1. New and existing drugs interfering with the renin-angiotensin (Ang) system cascade. Classically, interference occurs at the level of renin, angiotensin-converting enzyme (ACE), the Ang II type 1 (AT_1) receptor (R), or the mineralocorticoid receptor (MR), with renin inhibitors, ACE inhibitors, AT_1 receptor blockers (ARBs), or MR antagonists. Novel enzyme inhibitors now target aminopeptidase A (APA), which generates Ang III (=Ang-[1-7]) from Ang II (=Ang-[1-8]), or aldosterone synthase (CYP11B2). Activators of ACE2 (XNT and diminazene), which generates Ang-(1-7) from Ang II, were recently found to act equally well in ACE2 knockout animals, thus questioning their mechanism of action. Numerous agonists for both the AT_2 receptor and Mas receptor are being developed. Aminopeptidase N (APN) degrades Ang III to Ang IV (=Ang-[3-8]), which may act on the AT_4 receptor, also known as insulin-regulated aminopeptidase (IRAP). Figure reprinted with permission of the American Heart Association⁵⁷.

ability to block AT₁ receptors¹⁸. However, only a prospective, randomized, dose-escalation study can truly test whether azilsartan is superior to other ARBs at lowering BP.

Direct renin inhibitors

Renin secretion, a rate-limiting step, is the first step of the RAAS cascade. Renin has a unique specificity for its substrate angiotensin. Inhibition of renin provides an attractive option to inhibit the RAAS from its origin. The development of DRI started more than 30 years ago¹⁹, but there were issues with potency, bioavailability, and cost. Currently, aliskiren is the only approved DRI for use in HTN²⁰, and a significant BP reduction has been demonstrated in patients with essential HTN^{21,22}. Aliskiren is well tolerated and has a similar dose-dependent BP reduction in hypertensive patients as ARBs and a safety profile similar to that of placebo^{23,24}.

However, several recent studies have shown either no benefit or even harmful effects of aliskiren in certain populations. The ALTI-TUDE (Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints)²⁵ trial randomly assigned patients with type 2 diabetes and chronic kidney disease (CKD) or with cardiovascular disease (or with all three) already receiving an ACEI or ARB to aliskiren or placebo. Although there was a lower BP in the aliskiren arm, there was no reduction in the primary composite outcome, which included cardiovascular and renal events and mortality (hazard ratio [HR] 1.08, 95% confidence interval [CI] 0.98–1.20). In the ATMOSPHERE²⁶ trial (Aliskiren Trial to Minimize Outcomes in Patients with Heart failure), the addition of aliskiren to enalapril in patients with chronic heart failure was not associated with reduction in adverse outcomes (see “Recent clinical trials” section for details). Similarly, no improvement in coronary atherosclerosis in pre-hypertensive patients (AQUARIUS)²⁷ or improvement in cardiovascular outcomes in patients hospitalized with heart failure (ASTRONAUT)²⁸ was seen with aliskiren compared with placebo. Given the lack of demonstrated benefit and increased rates of adverse events such as hyperkalemia, hypotension, and renal impairment as seen in ASTRONAUT when combined with ACEIs or ARBs, the current use of aliskiren is limited²⁸.

Mineralocorticoid receptor antagonists

MRAs competitively inhibit mineralocorticoid receptors and decrease the number of epithelial sodium channels in the distal renal tubule²⁹. Spironolactone, an MRA, has long been used for the treatment of HTN; however, its non-specificity for mineralocorticoid receptors manifests as anti-androgenic and progestational effects^{30,31}. Spironolactone was found to be the most effective add-on anti-hypertensive drug when compared with doxazosin and bisoprolol in treating resistant HTN in the PATHWAY-2 trial³². This trial supports the important role of sodium retention in resistant HTN. Eplerenone, an MRA with lower affinity to progesterone and androgen receptors than spironolactone²⁹, has been shown to be efficacious even using ambulatory monitoring studies³³ and safe in the management of HTN. When compared with enalapril³⁴, losartan³⁵, and amlodipine³⁶, eplerenone monotherapy was as efficacious in treating HTN.

Currently, third- and fourth-generation MRAs are being developed to have the potency of spironolactone and the selectivity of

eplerenone³⁷. Finerenone, a novel non-steroidal MRA, has a greater affinity to the mineralocorticoid receptor than does eplerenone³⁸ and greater selectivity than does spironolactone³⁹. The Mineralocorticoid Receptor Antagonist Tolerability Study (ARTS) showed that finerenone (2.5–10 mg per day), in patients with CKD and albuminuria, decreased albuminuria with lower rates of hyperkalemia compared with spironolactone⁴⁰. With the recent development of patiromer, a non-absorbed potassium binder, a safe option for the treatment of chronic hyperkalemia is available, maintaining and using RAAS inhibitors including spironolactone, in CKD and heart failure⁴¹. Patiromer has also been shown to decrease potassium and aldosterone levels in patients with CKD and hyperkalemia on RAAS inhibitors independent of renin activity⁴². The recent ARTS-DN (Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy) study demonstrated greater reduction in albuminuria with the addition of finerenone to ACEI or ARB in patients with diabetic nephropathy compared with placebo (see “Recent clinical trials” section for details)^{43,44}.

Aldosterone synthase inhibitors

Another way of blocking the effects of mineralocorticoid receptor activation is to inhibit aldosterone formation. LCI699 is a potent first-in-class aldosterone synthase inhibitor. In patients with primary aldosteronism, LCI699 (up to 1.0 mg twice a day) caused modest reduction in 24-hour systolic BP (SBP) and office SBP compared with placebo⁴⁵. One mg of LCI699 was not superior to eplerenone 50 mg in reducing ambulatory SBP in patients with stage 1 or 2 HTN⁴⁶. LCI699 significantly lowered office and ambulatory BP in patients with primary HTN, but 20% of the patients on LCI699 developed blunted cortisol release⁴⁶. Because of this non-specificity, the development of LCI699 has been stopped in favor of developing more specific inhibitors.

Aminopeptidase A inhibitor

Functional RAAS may be present in the brain⁴⁷, and several animal models have demonstrated that hyperactivity of brain RAAS may contribute to HTN^{48,49}. Brain aminopeptidase A (APA) converts angiotensin II to angiotensin III. APA inhibition by EC33 has been shown to be a novel anti-hypertensive agent in animals^{50–52}. QGC001, an orally active prodrug of EC33, was tolerated in healthy normotensive human males but with no changes in renin, aldosterone, BP, or heart rate^{53–56}. This study demonstrates that QGC001, the first drug in its class, can be safely administered to humans, but further studies are required to assess the safety and efficacy of QGC001 in patients with HTN. Additional research on novel ways to block the RAAS, including development of prorenin blockade, gene- and vaccine-based strategies, and targeting ACE2, is being developed but has not yet translated into the clinic^{57,58}.

Predictors of renin-angiotensin-aldosterone system blockade response in patients with hypertension

In this section, we will review recent advances in understanding characteristics that may predispose patients to a greater response to RAAS blockade.

Plasma renin activity

Patients with high plasma renin activity (PRA) respond well to RAAS blockers, some of which suppress renin release^{59–62}. For

example, patients with elevated renin had a greater BP-lowering response to atenolol, an agent that suppresses renin release, than a diuretic^{60,61}. In contrast, in patients with low renin, anti-renin drugs (including aliskiren) may exert a pressor effect^{61,63}.

Using PRA levels as a treatment strategy is currently being tested as a way to improve BP control^{64,65}. Egan *et al.* showed that, in patients with uncontrolled HTN, ambulatory PRA provides information on the extracellular fluid and plasma volume⁶⁴. In their trial, a “renin test-guided therapeutic (RTGT) algorithm” targeted RAAS blockers to patients with high renin. The RTGT resulted in greater reduction in SBP compared with clinical HTN specialist care (-29.1 ± 3.2 mmHg versus -19.2 ± 3.2 mmHg; $P = 0.003$). Therefore, it would seem logical to treat hypertensive patients with high PRA with anti-renin-angiotensin drugs as a first choice⁶⁴. Although targeting RAAS blockade to patients with high PRA may be an effective BP-lowering strategy, further studies on the effect of RTGT treatment on risk for clinically important end-points are needed before this strategy can be recommended.

Salt

Salt plays an important role in BP response to RAAS blockers, although the exact mechanism remains to be elucidated. High salt intake causes volume expansion and BP elevation, which leads to pressure-dependent tissue injury, including renal injury^{66–70}. RAAS inhibitors reverse the salt-induced renal injury in spontaneous hypertensive rats^{71–73}.

Kobori *et al.* showed that a high-salt diet decreased PRA and enhanced kidney angiotensinogen levels in Dahl-sensitive rats, contributing to HTN⁷⁴. An increase in angiotensin II contributes to activation of the mineralocorticoid receptor-dependent intracellular signaling pathway, perhaps via induction of reactive oxygen species, and it has been proposed that mineralocorticoid receptor activation can occur independently of aldosterone in salt-sensitive HTN^{75–77}. This has recently been demonstrated in a study of patients with resistant HTN. Ghazi *et al.* examined predictors of BP response to spironolactone in a retrospective analysis of 79 patients with resistant HTN⁷⁸. Patients with high urinary sodium excretion (200 mEq/24 hours) had a significantly greater BP reduction with spironolactone compared with patients with a lower excretion (<200 mEq/24 hours) ($P = 0.008$). After potential confounders, primary aldosteronism, serum aldosterone concentration, and serum potassium were controlled for, 24-hour urinary sodium excretion remained a significant, independent predictor ($P = 0.02$) of a favorable BP response, defined as an at least 10 mmHg reduction in office SBP. Despite its limitations, including its retrospective design, not using 24-hour ambulatory BP monitoring, and non-generalizability to the general HTN population with controlled BP, it is the first study to suggest the benefit of MRA in counteracting the effects of high-sodium diet in patients with HTN, irrespectively of their aldosterone status⁷⁸. Given the difficulty in modifying patients’ dietary habits, elevated 24-hour urine sodium excretion may be used to identify patients who are more likely to be responsive to spironolactone.

Ethnicity

It is well known that African-Americans (AAs) have a different response to RAAS blockers when compared with whites. This

might be due to several mechanisms, including salt sensitivity, low renin, and high aldosterone levels, which may be interrelated^{79–83}. In ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) and the blood pressure-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA), ACEIs were less effective in reducing BP in AAs compared with whites; however, no racial difference was observed in those randomly assigned to a diuretic^{84–86}. This effect is not limited to ACEIs. In a randomized placebo-controlled study in AAs with low renin and poorly controlled HTN, both spironolactone and amiloride lowered BP similarly in AAs and whites⁸⁷. However, AAs had a significantly better response to eplerenone than to losartan (ARB), whereas no difference in response between these two agents was found in whites⁸⁸. In patients with heart failure treated with spironolactone, AAs exhibit less hyperkalemia compared with whites when treated with MRAs⁸⁹.

A recent study on patients from New York City’s Health and Hospitals Corporation compared ACEI efficacy to calcium channel blocker (CCB), thiazide diuretics, and beta blockers in AAs. It included a cohort of 25,564 propensity score-matched hypertensive AA patients. ACEIs were associated with a higher risk of primary outcome (myocardial infarction, stroke, and heart failure) compared with CCB (4,506 matched pairs; HR 1.45, 95% CI 1.19–1.77; $P = 0.0003$), and a higher risk for primary outcome was observed when ACEIs were compared with thiazide diuretics in AAs (5,337 matched pairs; HR 1.65, 95% CI 1.33–2.05; $P < 0.0001$)⁹⁰. A meta-analysis of 13 different trials in the USA and Europe showed that SBP and diastolic BP reduction with ACEI monotherapy was consistently lower among AAs than among whites⁹¹. Therefore, as recommended by the members appointed to the Eighth Joint National Committee (JNC 8), initial anti-hypertensive therapy for the AA population should include a thiazide or CCB.

Sex

The RAAS is affected by sex hormones and plays a role in sex-related differences in BP; however, there are no specific guidelines that suggest sex-specific treatment^{57,92–94}. Estrogen attenuates the vasoconstrictor effect of the RAAS by decreasing renin, angiotensin, and nitric oxide synthase, but this attenuation will decrease once women reach menopause^{57,95,96}. Irbesartan, for example, has a greater BP-lowering effect in pre-menopausal women than in men⁹⁷. In a retrospective observational study of congestive heart failure (CHF), women had a better survival with ARBs than with ACEIs whether they were hypertensive or not⁹⁸. In hypertensive men, their survival was comparable using an ARB or an ACEI. In non-hypertensive men, ACEIs were associated with better survival.

More recently, the Identification of the Determinants of the Efficacy of Arterial blood pressure Lowering drugs (IDEAL) trial set out to identify office SBP response to both an ACEI (perindopril) and a diuretic (indapamide) in untreated hypertensive patients (SBP ≥ 140 and <180 mmHg) between 25 and 70 years of age⁹⁹. For the 112 patients included in this cross-over study, the average BP responses were 7.2/4.0 mmHg for indapamide and 6.6/4.2 mmHg for perindopril. The response among women, without distinction among pre- or post-menopausal, was almost two times greater than in men for indapamide (mean effect of -11.5 mmHg for women

versus -4.8 mmHg for men; $P < 0.001$) and for perindopril (mean effect of -8.3 mmHg for women versus -4.3 mmHg for men; $P = 0.015$). Subgroup analysis of the response to indapamide by age revealed that an association was present in women and that there was an increase of the response by 3 mmHg for every 10 years of age ($P = 0.024$). Therefore, both age and sex were important determinants of BP response in the IDEAL population.

BP response to various RAAS blockades is affected by renin, salt, gender, ethnicity, and even age. However, all of those factors are likely interrelated. For instance, AAs have lower renin activity than do whites and have been shown to respond better to atenolol^{62,86}. Patients on a low-salt diet have higher renin activity⁵⁷.

Recent clinical trials

In this final section, we review a few recent pivotal trials of RAAS blockade.

ATMOSPHERE trial

RAAS blockade reduces the risk of death among patients with heart failure with reduced ejection fraction⁸. Dual blockade with an ACEI and aliskiren reduced N-terminal prohormone of brain natriuretic peptide (NT-proBNP). Therefore, the ATMOSPHERE trial²⁶ randomly assigned patients in a 1:1:1 fashion to aliskiren 300 mg once daily ($n = 2,340$), enalapril 5 or 10 mg twice daily ($n = 2,336$), or enalapril 5 or 10 mg twice daily + aliskiren 300 mg once daily ($n = 2,340$), and patients were followed-up for 36.6 months (interquartile range of 22.4 to 52.2). ATMOSPHERE included patients at least 18 years of age with chronic symptomatic heart failure (New York Heart Association functional class II–IV), left ventricular ejection fraction of not more than 35%, and an estimated glomerular filtration rate (eGFR) of at least 40 mL/minute per 1.73 m².

The Clinical Trials Facilitation Group of the Heads of Medicines Agencies in Europe requested discontinuation of ATMOSPHERE study drugs in diabetic patients following the results of the ALTITUDE and ASTRONAUT trials. Overall, there was no difference in the primary outcome, cardiovascular death, or CHF hospitalization for aliskiren + enalapril versus enalapril (32.9% versus 34.6%; HR 0.93, 95% CI 0.85–1.03; $P = 0.17$ for superiority) or for aliskiren versus enalapril (33.8% versus 34.6%; HR 0.99, 95% CI 0.90–1.10; $P = 0.91$ for superiority) ($P = 0.018$ for non-inferiority; not significant per pre-specified threshold). There were no differences in most of the secondary outcomes, but combination therapy was associated with increased risk for the composite renal outcome (HR 2.2, 95% CI 1.2–3.8). Combination therapy was also associated with increased risk for hypotension and hyperkalemia. In all, ATMOSPHERE indicates that aliskiren is not superior to enalapril either as monotherapy or as combination therapy in patients with heart failure with reduced ejection fraction.

ARTS-DN trial

Finerenone is a non-steroidal MRA that is equally efficacious as spironolactone at reducing BNP and albuminuria in patients with CKD and heart failure with reduced ejection fraction but has the added benefit of lower incidence of hyperkalemia⁴⁰. ARTS-DN was a multicenter, randomized trial designed to compare the effects of

finerenone 1.25 to 20 mg once daily with placebo when added to the standard of care with an RAAS blocker. Patients with type 2 diabetes mellitus, persistent albuminuria (urine albumin-to-creatinine ratio [UACR] of at least 30 mg/g), and eGFR of more than 30 mL/minute per 1.73 m² receiving treatment with the minimum recommended dosage of an RAAS blocker prior to the screening visit were included.

The primary outcome was the UACR at day 90 compared with baseline. Finerenone reduced UACR in a dose-dependent manner. The placebo-corrected geometric mean UACRs at day 90 to baseline in finerenone 7.5, 10, 15, and 20 mg groups were 0.79 (90% CI 0.68–0.91; $P = 0.004$), 0.76 (90% CI 0.65–0.88; $P = 0.001$), 0.67 (90% CI 0.58–0.77; $P < 0.001$), and 0.62 (90% CI 0.54–0.72; $P < 0.001$), respectively. The incidences of an eGFR decrease of at least 40% at any time after baseline were similar in the placebo and finerenone groups, and decreases in eGFR noted in the finerenone groups were reversible 30 days after completion of treatment. There was no reported difference in serious adverse events. This trial demonstrated that, in patients with diabetic nephropathy receiving an ACEI or ARB, adding finerenone compared with placebo improved UACR without an increased risk of hyperkalemia. Longer-term studies are needed to determine whether the addition of finerenone is renoprotective.

VA NEPHRON-D trial

The goal of the VA NEPHRON-D (Veterans Affairs Nephropathy in Diabetes) trial¹⁰⁰ was to evaluate whether combination treatment with ACEI (lisinopril) and ARB (losartan) compared with ARB alone in patients with diabetic nephropathy slows the progression of CKD. Patients with diabetes, eGFR of 30.0–89.9 mL/minute per 1.73 m², and a UACR of more than 300 mg/g were included. After 2.2 years, the primary outcome of decrease in eGFR, end-stage renal disease, or death occurred in 18.2% of participants in the combination ACEI/ARB group versus 21.0% of the ARB group (HR in combination group of 0.88, 95% CI 0.7–1.12; $P = 0.30$). There was increased risk for adverse events in the combination group versus ARB alone, including acute kidney injury (18.0% versus 11.0%; $P < 0.001$) and hyperkalemia (9.9% versus 4.4%; $P < 0.001$). The increased risk for adverse events led to early termination of the trial. Combined with the results of ONTARGET, VA NEPHRON-D confirms that there is no benefit but an increased risk of adverse events from dual inhibition from RAAS in high-risk patients.

Conclusions

Despite the large number and varying mechanisms of action of existing RAAS-blocking agents, complications such as hyperkalemia and acute kidney injury limit their use. Newer agents that are more specific, such as finerenone, are being developed and may provide the benefits of older RAAS-blocking agents with fewer complications and adverse effects. However, lessons learned from newer agents such as aliskiren indicate that long-term studies with hard end-points are required because outcomes from short-term trials with surrogate outcomes (for example, albuminuria and BNP) may not be consistent with long-term trials with hard clinical end-points. Insight from mechanistic studies and retrospective analyses will inform the design of these trials to target patients most likely to benefit from RAAS blockade, further refining our approach of the use of RAAS blockers in the treatment of HTN.

Competing interests

The authors declare that they have no competing interests.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

- Gavras H, Brunner HR, Turini GA, *et al.*: Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. *N Engl J Med.* 1978; 298(18): 991–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Chobanian AV, Bakris GL, Black HR, *et al.*: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA.* 2003; 289(19): 2560–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Mancia G, De Backer G, Dominiczak A, *et al.*: 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens.* 2007; 25(6): 1105–87.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Der Sarkissian S, Huentelman MJ, Stewart J, *et al.*: ACE2: A novel therapeutic target for cardiovascular diseases. *Prog Biophys Mol Biol.* 2006; 91(1–2): 163–98.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Yusuf S, Sleight P, Pogue J, *et al.*: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. *N Engl J Med.* 2000; 342(3): 145–53.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. *Lancet.* 2000; 355(9200): 253–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Fox KM, EUROpean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet.* 2003; 362(9386): 782–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. *N Engl J Med.* 1991; 325(5): 293–302.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Hansson L, Lindholm LH, Niskanen L, *et al.*: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. *Lancet.* 1999; 353(9153): 611–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Brenner BM, Cooper ME, de Zeeuw D, *et al.*: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med.* 2001; 345(12): 861–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Lewis EJ, Hunsicker LG, Clarke WR, *et al.*: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med.* 2001; 345(12): 851–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
- ONTARGET Investigators, Yusuf S, Teo KK, *et al.*: Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med.* 2008; 358(15): 1547–59.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Barnett AH, Bain SC, Bouter P, *et al.*: Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. *N Engl J Med.* 2004; 351(19): 1952–61.
[PubMed Abstract](#) | [Publisher Full Text](#)
- White WB, Weber MA, Sica D, *et al.*: Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension. *Hypertension.* 2011; 57(3): 413–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Sica D, White WB, Weber MA, *et al.*: Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. *J Clin Hypertens (Greenwich).* 2011; 13(7): 467–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Bakris GL, Sica D, Weber M, *et al.*: The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. *J Clin Hypertens (Greenwich).* 2011; 13(2): 81–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gitt AK, Bramlage P, Potthoff SA, *et al.*: Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry. *BMC Cardiovasc Disord.* 2016; 16: 56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- Kurtz TW, Kajiya T: Differential pharmacology and benefit/risk of azilsartan compared to other sartans. *Vasc Health Risk Manag.* 2012; 8: 133–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Skeggs LT Jr, Kahn JR, Lentz K, *et al.*: The preparation, purification, and amino acid sequence of a polypeptide renin substrate. *J Exp Med.* 1957; 106(3): 439–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Gradman AH, Kad R: Renin inhibition in hypertension. *J Am Coll Cardiol.* 2008; 51(5): 519–28.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Villamil A, Chrysant SG, Calhoun D, *et al.*: Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. *J Hypertens.* 2007; 25(1): 217–26.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Schmieder RE, Philipp T, Guerdiaga J, *et al.*: Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. *Circulation.* 2009; 119(3): 417–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Allikmets K: Aliskiren—an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension. *Vasc Health Risk Manag.* 2007; 3(6): 809–15.
[PubMed Abstract](#) | [Free Full Text](#)
- Nussberger J, Wuerzner G, Jensen C, *et al.*: Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. *Hypertension.* 2002; 39(1): E1–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Parving HH, Brenner BM, McMurray JJ, *et al.*: Cardiorenal end points in a trial of aliskiren for type 2 diabetes. *N Engl J Med.* 2012; 367(23): 2204–13.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- McMurray JJ, Krum H, Abraham WT, *et al.*: Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. *N Engl J Med.* 2016; 374(16): 1521–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Nicholls SJ, Bakris GL, Kastelein JJ, *et al.*: Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. *JAMA.* 2013; 310(11): 1135–44.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- Gheorghiadu M, Böhm M, Greene SJ, *et al.*: Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. *JAMA.* 2013; 309(11): 1125–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
- de Gasparo M, Joss U, Ramjouw HP, *et al.*: Three new epoxy-spirolactone derivatives: characterization *in vivo* and *in vitro*. *J Pharmacol Exp Ther.* 1987; 240(2): 650–6.
[PubMed Abstract](#)
- Ménard J: The 45-year story of the development of an anti-aldosterone more specific than spironolactone. *Mol Cell Endocrinol.* 2004; 217(1–2): 45–52.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Pitt B, Zannad F, Remme WJ, *et al.*: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med.* 1999; 341(10): 709–17.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Williams B, MacDonald TM, Morant S, *et al.*: Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. *Lancet.* 2015; 386(10008): 2059–68.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
- White WB, Carr AA, Krause S, *et al.*: Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. *Am J Cardiol.* 2003; 92(1): 38–42.
[PubMed Abstract](#) | [Publisher Full Text](#)

34. Williams GH, Burgess E, Kolloch RE, *et al.*: **Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension.** *Am J Cardiol.* 2004; **93**(8): 990–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Weinberger MH, White WB, Rulope L, *et al.*: **Effects of eplerenone versus losartan in patients with low-renin hypertension.** *Am Heart J.* 2005; **150**(3): 426–33.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. White WB, Duprez D, St Hilaire R, *et al.*: **Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.** *Hypertension.* 2003; **41**(5): 1021–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Funder JW: **Aldosterone and mineralocorticoid receptors in the cardiovascular system.** *Prog Cardiovasc Dis.* 2010; **52**(5): 393–400.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. F Kolkhof P, Delbeck M, Kretschmer A, *et al.*: **Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.** *J Cardiovasc Pharmacol.* 2014; **64**(1): 69–78.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
39. F Bärfacker L, Kuhl A, Hillisch A, *et al.*: **Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases.** *ChemMedChem.* 2012; **7**(8): 1385–403.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
40. F Pitt B, Kober L, Ponikowski P, *et al.*: **Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.** *Eur Heart J.* 2013; **34**(31): 2453–63.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
41. F Pitt B, Bakris GL, Bushinsky DA, *et al.*: **Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors.** *Eur J Heart Fail.* 2015; **17**(10): 1057–65.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
42. F Weir MR, Bakris GL, Gross C, *et al.*: **Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.** *Kidney Int.* 2016; **90**(3): 696–704.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
43. F Bakris GL, Agarwal R, Chan JC, *et al.*: **Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.** *JAMA.* 2015; **314**(9): 884–94.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
44. Holtkamp FA, de Zeeuw D, de Graef PA, *et al.*: **Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials.** *Eur Heart J.* 2011; **32**(12): 1493–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
45. Amar L, Azizi M, Menard J, *et al.*: **Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism.** *Hypertension.* 2010; **56**(5): 831–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
46. Calhoun DA, White WB, Krum H, *et al.*: **Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.** *Circulation.* 2011; **124**(18): 1945–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
47. Wright JW, Harding JW: **Regulatory role of brain angiotensins in the control of physiological and behavioral responses.** *Brain Res Brain Res Rev.* 1992; **17**(3): 227–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
48. Basso N, Ruiz P, Kurnjek ML, *et al.*: **The brain renin-angiotensin system and the development of DOC-salt hypertension.** *Clin Exp Hypertens A.* 1985; **7**(9): 1259–68.
[PubMed Abstract](#) | [Publisher Full Text](#)
49. Ganten D, Hermann K, Bayer C, *et al.*: **Angiotensin synthesis in the brain and increased turnover in hypertensive rats.** *Science.* 1983; **221**(4613): 869–71.
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Zini S, Fournie-Zaluski MC, Chauvel E, *et al.*: **Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release.** *Proc Natl Acad Sci U S A.* 1996; **93**(21): 11968–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Reaux A, Fournie-Zaluski MC, David C, *et al.*: **Aminopeptidase A inhibitors as potential central antihypertensive agents.** *Proc Natl Acad Sci U S A.* 1999; **96**(23): 13415–20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
52. Reaux A, Fournie-Zaluski MC, Llorens-Cortes C: **Angiotensin III: a central regulator of vasopressin release and blood pressure.** *Trends Endocrinol Metab.* 2001; **12**(4): 157–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
53. F Balavoine F, Azizi M, Bergerot D, *et al.*: **Randomised, double-blind, placebo-controlled, dose-escalating phase I study of QGC001, a centrally acting aminopeptidase A inhibitor prodrug.** *Clin Pharmacokinet.* 2014; **53**(4): 385–95.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
54. Fournie-Zaluski MC, Fassot C, Valentin B, *et al.*: **Brain renin-angiotensin system blockade by systemically active aminopeptidase A inhibitors: a potential treatment of salt-dependent hypertension.** *Proc Natl Acad Sci U S A.* 2004; **101**(20): 7775–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
55. Bodineau L, Frugièr A, Marc Y, *et al.*: **Orally active aminopeptidase A inhibitors reduce blood pressure: a new strategy for treating hypertension.** *Hypertension.* 2008; **51**(5): 1318–25.
[PubMed Abstract](#) | [Publisher Full Text](#)
56. Marc Y, Gao J, Balavoine F, *et al.*: **Central antihypertensive effects of orally active aminopeptidase A inhibitors in spontaneously hypertensive rats.** *Hypertension.* 2012; **60**(2): 411–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
57. F Te Riet L, van Esch JH, Roks AJ, *et al.*: **Hypertension: renin-angiotensin-aldosterone system alterations.** *Circ Res.* 2015; **116**(6): 960–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
58. Do TH, Chen Y, Nguyen VT, *et al.*: **Vaccines in the management of hypertension.** *Expert Opin Biol Ther.* 2010; **10**(7): 1077–87.
[PubMed Abstract](#) | [Publisher Full Text](#)
59. Laragh JH, Sealey JE: **The plasma renin test reveals the contribution of body sodium-volume content (V) and renin-angiotensin (R) vasoconstriction to long-term blood pressure.** *Am J Hypertens.* 2011; **24**(11): 1164–80.
[PubMed Abstract](#) | [Publisher Full Text](#)
60. Turner ST, Schwartz GL, Chapman AB, *et al.*: **Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension.** *Am J Hypertens.* 2010; **23**(9): 1014–22.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
61. Alderman MH, Cohen HW, Sealey JE, *et al.*: **Pressor responses to antihypertensive drug types.** *Am J Hypertens.* 2010; **23**(9): 1031–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
62. F Tu W, Eckert GJ, Pratt JH, *et al.*: **Plasma levels of prorenin and renin in blacks and whites: their relative abundance and associations with plasma aldosterone concentration.** *Am J Hypertens.* 2012; **25**(9): 1030–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
63. Sealey JE, Laragh JH: **Aliskiren fails to lower blood pressure in patients who have either low PRA levels or whose PRA falls insufficiently or reactively rises.** *Am J Hypertens.* 2009; **22**(1): 112–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
64. Egan BM, Basile JN, Rehman SU, *et al.*: **Plasma Renin test-guided drug treatment algorithm for correcting patients with treated but uncontrolled hypertension: a randomized controlled trial.** *Am J Hypertens.* 2009; **22**(7): 792–801.
[PubMed Abstract](#) | [Publisher Full Text](#)
65. Sim JJ, Bhandari SK, Shi J, *et al.*: **Plasma renin activity (PRA) levels and antihypertensive drug use in a large healthcare system.** *Am J Hypertens.* 2012; **25**(3): 379–88.
[PubMed Abstract](#) | [Publisher Full Text](#)
66. de Wardener HE, He FJ, MacGregor GA: **Plasma sodium and hypertension.** *Kidney Int.* 2004; **66**(6): 2454–66.
[PubMed Abstract](#) | [Publisher Full Text](#)
67. Titze J, Machnik A: **Sodium sensing in the interstitium and relationship to hypertension.** *Curr Opin Nephrol Hypertens.* 2010; **19**(4): 385–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
68. F Schmidlin O, Forman A, Leone A, *et al.*: **Salt sensitivity in blacks: evidence that the initial pressor effect of NaCl involves inhibition of vasodilatation by asymmetrical dimethylarginine.** *Hypertension.* 2011; **58**(3): 380–5.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
69. Ying WZ, Sanders PW: **Dietary salt intake activates MAP kinases in the rat kidney.** *FASEB J.* 2002; **16**(12): 1683–4.
[PubMed Abstract](#)
70. Chandramohan G, Bai Y, Norris K, *et al.*: **Effects of dietary salt on intrarenal angiotensin system, NAD(P)H oxidase, COX-2, MCP-1 and PAI-1 expressions and NF-kappaB activity in salt-sensitive and -resistant rat kidneys.** *Am J Nephrol.* 2008; **28**(1): 158–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
71. Susic D, Zhou X, Frohlich ED: **Angiotensin blockade prevents salt-induced injury of the renal circulation in spontaneously hypertensive rats.** *Am J Nephrol.* 2009; **29**(6): 639–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
72. Varagic J, Frohlich ED, Susic D, *et al.*: **AT₁ receptor antagonism attenuates target organ effects of salt excess in SHR without affecting pressure.** *Am J Physiol Heart Circ Physiol.* 2008; **294**(2): H853–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
73. Susic D, Frohlich ED, Kobori H, *et al.*: **Salt-induced renal injury in SHR is mediated by AT₁ receptor activation.** *J Hypertens.* 2011; **29**(4): 716–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
74. Kobori H, Nishiyama A, Abe Y, *et al.*: **Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet.** *Hypertension.* 2003; **41**(3): 592–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
75. F Jaffe IZ, Mendelsohn ME: **Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary**

- artery smooth muscle cells. *Circ Res*. 2005; **96**(6): 643–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
76. Fujita T: Aldosterone in salt-sensitive hypertension and metabolic syndrome. *J Mol Med (Berl)*. 2008; **86**(6): 729–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
 77. Shibata S, Nagase M, Yoshida S, *et al.*: Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. *Nat Med*. 2008; **14**(12): 1370–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 78. Ghazi L, Dudenbostel T, Lin CP, *et al.*: Urinary sodium excretion predicts blood pressure response to spironolactone in patients with resistant hypertension independent of aldosterone status. *J Hypertens*. 2016; **34**(5): 1005–10.
[PubMed Abstract](#) | [Publisher Full Text](#)
 79. Cruickshank JK, Anderson NM, Wadsworth J, *et al.*: Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol. *BMJ*. 1988; **297**(6657): 1155–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 80. Preston RA, Materson BJ, Reda DJ, *et al.*: Age-race subgroup compared with renin profile as predictors of blood pressure response to antihypertensive therapy. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. *JAMA*. 1998; **280**(13): 1168–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
 81. Weir MR, Chrysant SG, McCarron DA, *et al.*: Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. *Hypertension*. 1998; **31**(5): 1088–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 82. Helmer OM: The renin-angiotensin system and its relation to hypertension. *Prog Cardiovasc Dis*. 1965; **8**(2): 117–28.
[PubMed Abstract](#)
 83. Chrysant SG, Danisa K, Kem DC, *et al.*: Racial differences in pressure, volume and renin interrelationships in essential hypertension. *Hypertension*. 1979; **1**(2): 136–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
 84. Oparil S: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): practical implications. *Hypertension*. 2003; **41**(5): 1006–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 85. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. 2002; **288**(23): 2981–97.
[PubMed Abstract](#) | [Publisher Full Text](#)
 86. Gupta AK, Poulter NR, Dobson J, *et al.*: Ethnic differences in blood pressure response to first and second-line antihypertensive therapies in patients randomized in the ASCOT Trial. *Am J Hypertens*. 2010; **23**(9): 1023–30.
[PubMed Abstract](#) | [Publisher Full Text](#)
 87. Saha C, Eckert GJ, Ambrosius WT, *et al.*: Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. *Hypertension*. 2005; **46**(3): 481–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
 88. Flack JM, Oparil S, Pratt JH, *et al.*: Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. *J Am Coll Cardiol*. 2003; **41**(7): 1148–55.
[PubMed Abstract](#) | [Publisher Full Text](#)
 89. Cavallari LH, Fashingbauer LA, Beitelshes AL, *et al.*: Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure. *Pharmacotherapy*. 2004; **24**(6): 750–6.
[PubMed Abstract](#) | [Publisher Full Text](#)
 90. Bangalore S, Ogedegbe G, Gyamfi J, *et al.*: Outcomes with Angiotensin-converting Enzyme Inhibitors vs Other Antihypertensive Agents in Hypertensive Blacks. *Am J Med*. 2015; **128**(11): 1195–203.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 91. Peck RN, Smart LR, Beier R, *et al.*: Difference in blood pressure response to ACE-inhibitor monotherapy between black and white adults with arterial hypertension: a meta-analysis of 13 clinical trials. *BMC Nephrol*. 2013; **14**: 201.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 92. Ely DL, Turner ME: Hypertension in the spontaneously hypertensive rat is linked to the Y chromosome. *Hypertension*. 1990; **16**(3): 277–81.
[PubMed Abstract](#) | [Publisher Full Text](#)
 93. Arnold AP, Chen X: What does the “four core genotypes” mouse model tell us about sex differences in the brain and other tissues? *Front Neuroendocrinol*. 2009; **30**(1): 1–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 94. Ji H, Zheng W, Wu X, *et al.*: Sex chromosome effects unmasked in angiotensin II-induced hypertension. *Hypertension*. 2010; **55**(5): 1275–82.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 95. Schunkert H, Danser AH, Hense HW, *et al.*: Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. *Circulation*. 1997; **95**(1): 39–45.
[PubMed Abstract](#) | [Publisher Full Text](#)
 96. Hilliard LM, Sampson AK, Brown RD, *et al.*: The “his and hers” of the renin-angiotensin system. *Curr Hypertens Rep*. 2013; **15**(1): 71–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 97. Miller JA, Cherney DZ, Duncan JA, *et al.*: Gender differences in the renal response to renin-angiotensin system blockade. *J Am Soc Nephrol*. 2006; **17**(9): 2554–60.
[PubMed Abstract](#) | [Publisher Full Text](#)
 98. Hudson M, Rahme E, Behloul H, *et al.*: Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure—a population study. *Eur J Heart Fail*. 2007; **9**(6–7): 602–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
 99. Gueyffier F, Subtil F, Bejan-Angoulvant T, *et al.*: Can we identify response markers to antihypertensive drugs? First results from the IDEAL Trial. *J Hum Hypertens*. 2015; **29**(1): 22–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 100. Fried LF, Emanuele N, Zhang JH, *et al.*: Combined angiotensin inhibition for the treatment of diabetic nephropathy. *N Engl J Med*. 2013; **369**(20): 1892–903.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

- Bertram Pitt**
University of Michigan School of Medicine, Ann Arbor, MI, USA
Competing Interests: No competing interests were disclosed.
- Anton van den Meiracker**
Department of Internal Medicine, Erasmus Medical Centre, Rotterdam, The Netherlands
Competing Interests: No competing interests were disclosed.
- AK Johnson**
Department of Psychological and Brain Sciences, University of Iowa, Iowa City, IA, 52242, USA
Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research